Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders

Research output: Contribution to journalArticle

Abstract

The eye is a relatively isolated tissue compartment, which provides advantages for utilization of small interfering RNA (siRNA). Feasibility of using siRNA for treatment of choroidal neovascularization has been demonstrated using siRNA directed against vascular endothelial growth factor (VEGF) or VEGF receptor 1 (VEGFR1), and both of these approaches are being tested in clinical trials. The results with VEGFR1 siRNA show that VEGFR1 is proangiogenic in the eye and is not a decoy receptor as it is in developmental angiogenesis. Topical delivery of siRNAs directed against VEGF or its receptors has also been shown to suppress corneal neovascularization. Signaling through transforming growth factor-β receptor 2 (TGFβR2) has been implicated in excessive ocular scarring and TGFβR2 siRNA has shown benefit in a model relevant to excessive scarring after glaucoma filtration surgery. RNAi has been used to identify genes that promote apoptosis or oxidative damage in retinal cells and could be the basis of new treatments for glaucoma or photoreceptor degenerations. In cultured cells derived from ocular tissues, siRNA has become a valuable tool to explore the potential role of various genes in ocular disease processes. Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases.

Original languageEnglish (US)
Pages (from-to)559-562
Number of pages4
JournalGene Therapy
Volume13
Issue number6
DOIs
StatePublished - Mar 2006

Fingerprint

RNA Interference
Small Interfering RNA
Vascular Endothelial Growth Factor Receptor
Growth Factor Receptors
Eye Diseases
Transforming Growth Factors
Glaucoma
Vascular Endothelial Growth Factor A
Cicatrix
Corneal Neovascularization
Filtering Surgery
Vascular Endothelial Growth Factor Receptor-1
Choroidal Neovascularization
Genes
Cultured Cells
Clinical Trials
Apoptosis

ASJC Scopus subject areas

  • Genetics

Cite this

Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. / Campochiaro, Peter A.

In: Gene Therapy, Vol. 13, No. 6, 03.2006, p. 559-562.

Research output: Contribution to journalArticle

@article{4ffd533eaef9481c86ae62bcd7fedfea,
title = "Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders",
abstract = "The eye is a relatively isolated tissue compartment, which provides advantages for utilization of small interfering RNA (siRNA). Feasibility of using siRNA for treatment of choroidal neovascularization has been demonstrated using siRNA directed against vascular endothelial growth factor (VEGF) or VEGF receptor 1 (VEGFR1), and both of these approaches are being tested in clinical trials. The results with VEGFR1 siRNA show that VEGFR1 is proangiogenic in the eye and is not a decoy receptor as it is in developmental angiogenesis. Topical delivery of siRNAs directed against VEGF or its receptors has also been shown to suppress corneal neovascularization. Signaling through transforming growth factor-β receptor 2 (TGFβR2) has been implicated in excessive ocular scarring and TGFβR2 siRNA has shown benefit in a model relevant to excessive scarring after glaucoma filtration surgery. RNAi has been used to identify genes that promote apoptosis or oxidative damage in retinal cells and could be the basis of new treatments for glaucoma or photoreceptor degenerations. In cultured cells derived from ocular tissues, siRNA has become a valuable tool to explore the potential role of various genes in ocular disease processes. Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases.",
author = "Campochiaro, {Peter A}",
year = "2006",
month = "3",
doi = "10.1038/sj.gt.3302653",
language = "English (US)",
volume = "13",
pages = "559--562",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders

AU - Campochiaro, Peter A

PY - 2006/3

Y1 - 2006/3

N2 - The eye is a relatively isolated tissue compartment, which provides advantages for utilization of small interfering RNA (siRNA). Feasibility of using siRNA for treatment of choroidal neovascularization has been demonstrated using siRNA directed against vascular endothelial growth factor (VEGF) or VEGF receptor 1 (VEGFR1), and both of these approaches are being tested in clinical trials. The results with VEGFR1 siRNA show that VEGFR1 is proangiogenic in the eye and is not a decoy receptor as it is in developmental angiogenesis. Topical delivery of siRNAs directed against VEGF or its receptors has also been shown to suppress corneal neovascularization. Signaling through transforming growth factor-β receptor 2 (TGFβR2) has been implicated in excessive ocular scarring and TGFβR2 siRNA has shown benefit in a model relevant to excessive scarring after glaucoma filtration surgery. RNAi has been used to identify genes that promote apoptosis or oxidative damage in retinal cells and could be the basis of new treatments for glaucoma or photoreceptor degenerations. In cultured cells derived from ocular tissues, siRNA has become a valuable tool to explore the potential role of various genes in ocular disease processes. Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases.

AB - The eye is a relatively isolated tissue compartment, which provides advantages for utilization of small interfering RNA (siRNA). Feasibility of using siRNA for treatment of choroidal neovascularization has been demonstrated using siRNA directed against vascular endothelial growth factor (VEGF) or VEGF receptor 1 (VEGFR1), and both of these approaches are being tested in clinical trials. The results with VEGFR1 siRNA show that VEGFR1 is proangiogenic in the eye and is not a decoy receptor as it is in developmental angiogenesis. Topical delivery of siRNAs directed against VEGF or its receptors has also been shown to suppress corneal neovascularization. Signaling through transforming growth factor-β receptor 2 (TGFβR2) has been implicated in excessive ocular scarring and TGFβR2 siRNA has shown benefit in a model relevant to excessive scarring after glaucoma filtration surgery. RNAi has been used to identify genes that promote apoptosis or oxidative damage in retinal cells and could be the basis of new treatments for glaucoma or photoreceptor degenerations. In cultured cells derived from ocular tissues, siRNA has become a valuable tool to explore the potential role of various genes in ocular disease processes. Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases.

UR - http://www.scopus.com/inward/record.url?scp=33645139836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645139836&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302653

DO - 10.1038/sj.gt.3302653

M3 - Article

C2 - 16195702

AN - SCOPUS:33645139836

VL - 13

SP - 559

EP - 562

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -